PWM
WST icon

Proathlete Wealth Management’s West Pharmaceutical WST Stock Holding History

Proathlete Wealth Management’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.15K Hold
6
– – ﹤0.01% 208
2026
Q1 		$1.5K Hold
6
– – ﹤0.01% 234
2025
Q4 		$1.65K Buy
+6
New +$1.64K ﹤0.01% 242

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Proathlete Wealth Management's WST Position: Q2 2026 in Review

Proathlete Wealth Management held its West Pharmaceutical (WST) position steady in Q2 2026 at 6 shares worth $2.15K. The position accounts for ﹤0.01% of the portfolio, ranked #208.

Proathlete Wealth Management first reported a position in WST in Q4 2025 and has held it in 3 quarters since. 831 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • Proathlete Wealth Management held 6 shares of West Pharmaceutical worth $2.15K as of Q2 2026.
  • Proathlete Wealth Management left its West Pharmaceutical share count unchanged in Q2 2026.
  • West Pharmaceutical made up ﹤0.01% of Proathlete Wealth Management's portfolio in Q2 2026, its #208 holding.
  • Proathlete Wealth Management first reported a position in West Pharmaceutical in Q4 2025 and has held it in 3 quarters since.
  • 831 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Proathlete Wealth Management's 13F filing for Q2 2026, filed 21 Jul 2026.